Skip to main content

Table 3 FMF-50 response criteria

From: Assessment of effectiveness of anakinra and canakinumab in patients with colchicine-resistant/unresponsive familial Mediterranean fever

ParametersAt least 50% reduction
Attack frequency63/65 (96.9%)
Durations of attacks63/65 (96.9%)
Patients VAS64/65 (98.5%)
Physicians VAS64/65 (98.5%)
CRP (at least 2 weeks after the last attack)62/65 (95.3%)
Arthritis9/11 (81.8%)
  1. Values presented by % frequency. VAS Visual Analogue Scale, CRP C reactive protein